Table 2.

Incidence of grade ≥3 AEs

System organ class MedDRA preferred term	Danvatirsen monotherapy (cohort 1) N=5	Danvatirsen+durvalumab (cohort 2) N=6
Patients with any AE	3 (60.0)	6 (100.0)
Metabolism and nutrition disorders	2 (40.0)	1 (16.7)
Hypermagnesaemia	1 (20.0)	0
Hypertriglyceridaemia	0	1 (16.7)
Hypokalaemia	1 (20.0)	0
Gastrointestinal disorders	1 (20.0)	0
Pancreatitis	1 (20.0)	0
Hepatobiliary disorders	0	2 (33.3)
Hepatic function abnormal (ALT/AST/γGT increased)	0	2 (33.3)
Investigations	1 (20.0)	3 (50.0)
Neutrophil count decreased	0	2 (33.3)
ALT increased	1 (20.0)	0
AST increased	1 (20.0)	0
Blood bilirubin increased	1 (20.0)	0
γGT increased	1 (20.0)	1 (16.7)
Platelet count decreased	0	1 (16.7)

Data are n (%).

AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γGT, gamma-glutamyl transferase.